Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92847
UPID:
GHSR_HUMAN
Alternative names:
GH-releasing peptide receptor; Ghrelin receptor
Alternative UPACC:
Q92847; Q14D12; Q6ISR8; Q92848; Q96RJ7
Background:
The Growth hormone secretagogue receptor type 1, also known as the Ghrelin receptor or GH-releasing peptide receptor, plays a pivotal role in stimulating growth hormone secretion. It interacts with a variety of ligands, including ghrelin, growth hormone releasing peptides (GHRP), and non-peptide secretagogues, showcasing its versatility in regulating growth processes.
Therapeutic significance:
Linked to isolated partial growth hormone deficiency, this receptor's dysfunction can lead to growth delay and short stature, among other symptoms. Targeting the Ghrelin receptor could offer novel therapeutic avenues for treating growth hormone deficiencies and related metabolic disorders.